PharmaNutra S.p.A.
PHN.XMIL
PharmaNutra S.p.A. is an Italian pharmaceutical and nutraceutical company specializing in the research, development, production, and marketing of innovative nutritional supplements and medical devices. Headquartered in Pisa and founded in 2003, it is renowned for its leadership in iron-based supplements under the SiderAL® trademark, utilizing patented Sucrosomial® Technology to treat iron deficiencies and support immune health, with over 130 published scientific papers validating efficacy. The company also offers products for joint health via the Cetilar® brand, pregnancy nutrition, muscle and joint support, sports nutrition, ophthalmic care, and night rest solutions, alongside raw materials and bioimpedance analysis devices through its Akern subsidiary. With 118 employees, PharmaNutra distributes domestically via over 160 medical representatives to pharmacies and parapharmacies, and internationally to more than 60 countries through 40 partners, focusing on Europe, the Middle East, South America, and the Far East. Its commitment to proprietary raw materials, patents, and clinical data underscores its role in advancing healthcare and wellness solutions. Key figures include Chairman and CEO Andrea Lacorte and COO Carlo Volpi. PharmaNutra S.p.A. plays a vital part in the healthcare sector, particularly in specialty pharmaceuticals and nutraceuticals.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€140M
▲ +14.0% YoY
Net Income (TTM)
€21M
▲ +20.8% YoY
Op. Margin
22.62%
▼ -0.9pp YoY
ROIC
26.85%
▲ +2.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€16M
▲ +1.1% YoY
Op. Cash Flow (TTM)
€18M
▲ +1.1% YoY
Net Debt
€2M
Cash & Equiv.
€19M
3Y CAGR: +16.4%
Continue Research
Peers
Drug Manufacturers - Specialty & Generic · Pick stocks to compare with PHN.XMIL
Held by ETFs
PHN.XMIL is in 3 US ETFs. The largest of them, with PHN.XMIL's weight in each:
PharmaNutra S.p.A. (PHN.XMIL) in four numbers
Questions about PharmaNutra S.p.A.
Is PharmaNutra S.p.A. (PHN.XMIL) overvalued?
At €84.70, PharmaNutra S.p.A.'s price is 21% above the €69.98 a share fair value that Intrinsiqq's calculator gets from its earnings. It trades at 39.29 times earnings and 50.78 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is PharmaNutra S.p.A.'s fair value?
Intrinsiqq's calculator puts PharmaNutra S.p.A.'s fair value at €69.98 a share. It grows earnings per share 10.1% a year for 5 years, applies an exit P/E of 30, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of €52.49. Every input can be changed on the Intrinsic Value tab.
Is PharmaNutra S.p.A. a high-quality business?
PharmaNutra S.p.A. scores 53 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 8 checks computed from company filings. Its best check is revenue growth at 13.7%, and its weakest is margin trend at -5.0pp. The Quality tab shows every check against its target.
Does PharmaNutra S.p.A. (PHN.XMIL) pay a dividend, and how much?
Yes. PharmaNutra S.p.A. (PHN.XMIL) pays a dividend: €1.00 per share over the last twelve months, a dividend yield of 1.20% at the latest close. It has raised its dividend per share for at least 5 years in a row, growing at 12.4% a year over the last 5 years. The payout takes about 46.5% of earnings.
Source: company filings. Price: last close 17 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PHN.XMIL
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.